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1. Introduction 
Melanoma is the deadliest form of skin cancer and responsible for 4% of all cancer deaths 
and 86% of skin cancer-related deaths in the United States (Losina et al., 2007). Melanoma is 
caused by malignant growth of the melanocytes, which are melanin-producing cells found 
in the skin’s epidermis, hair, and eyes. In melanoma, these cells undergo an uncontrollable 
cell growth that manifests in the skin, the nail bed, and sometimes although rarely in the 
eyes and mucous membrane (Garbe et al., 2010).  
Melanomas can be classified clinically into four major classes (Table 1). Most melanomas are 
superficially spreading malignant melanoma. Rare melanomas include amelanotic 
melanoma, splitzoid melanoma, desmoplastic melanoma, malignant blue nevus, ocular 
melanoma, and mucosa melanoma. Melanomas usually have an initial radial growth phase 
followed by a vertical growth phase. The radial growth is mostly intraepidermal, and is 
considered preinvasive or minimally invasive. In contrast, the vertical growth is invasion   
 
TYPE CHARACTERISTICS RADIAL 
GROWTH 
VERTICAL 
GROWTH 
PROGNOSIS 
Superficially 
spreading 
malignant 
melanoma 
Occurs at any site, frequently at 
the torso in males and the legs in 
females 
Months – 2 
years 
Delayed Variable 
Nodular 
melanoma 
Occurs at any site, frequently at 
trunk, head, neck 
Most rapidly growing and 
aggressive melanoma 
Not 
clinically 
observable 
Rapid Poor (due to advance 
stage at diagnosis) 
Lentigo 
maligna 
melanoma 
Tends to occur on sun-damaged 
skin in the elderly, particularly 
at the head and neck 
Mostly slow growth 
Years Much 
delayed 
Favourable 
Acral 
lentiginous 
melanoma 
Occurs at the palms, soles, and 
subungual 
Months – 
years 
Early Poor (due to advance 
stage at diagnosis) 
Table 1. The four major clinical classifications of melanoma (Wolff & Johnson, 2009; Duncan, 
2009) 
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into the dermis, and allows for a higher risk of metastasis due to its proximity to blood 
vessels (Wolff & Johnson, 2009). 
1.1 Diagnosis 
Typically, melanomas are detected as changes in the skin, often in or near an already 
existing mole. Normal moles are round to oval in shape with a homogeneous colour, and 
have a distinctive border. In contrast, melanoma can present as a change in the colour, shape, 
or diameter of a mole, which might also be painful, bleeding, or itchy. When suspecting 
melanoma, lesions can be characterized by the ‘ABCDE rule’ (Wolff & Johnson, 2009). This is 
accomplished by first, determining whether there is asymmetry in the shape of the lesion by 
comparing one-half to the other, then by inspecting whether the border of the lesion is 
irregular or poorly defined, as well as if the colour is heterogeneous and varying from one 
area to another. Also, there is reason for suspicion if the diameter is greater than 6 mm, and 
if the lesion is elevated or has a history of enlargement. However, it should be noted that 
these rules are more sensitive than specific (Marsden et al., 2010; Wolff & Johnson, 2009). 
The gold standard for diagnosing melanoma continues to be histopathology from an 
excision biopsy. Features on the histopathology that are useful for determining the 
prognosis include the thickness measured by the Breslow depth, whether there is ulceration, 
vascular invasion, microscopic satellites, and the mitotic count (Dummer et al., 2010). 
Breslow method of determining the tumour thickness is the greatest single prognostic 
variable, and is therefore of importance when choosing treatment options (see other 
chapters). Ulceration also usually indicates a worst prognosis. 
Once the diagnosis is confirmed, melanoma staging is useful when determining the 
treatment options. Staging usually follows the tumour-node-metastasis (TNM) classification 
endorsed by the American Joint Committee on Cancer (AJCC), which evaluates the primary 
tumour, regional nodes, and metastases (Table 2). Recently, dermoscopy by experienced and 
trained physicians have shown to enhance diagnostic accuracy (Garbe et al., 2010). 
Additionally, a sentinel lymph node biopsy (SLNB) is often used to stage melanoma because 
cancer cells frequently travel to the closest lymph nodes when they first spread.  
1.2 Treatment 
Melanoma in situ is the earliest stage and is 99% curable with just surgical removal of the 
tumour. With increasing melanoma stages, other treatments in addition to surgery need to 
be considered. They include radiation therapy, chemotherapy, immunotherapy, and other 
interventions. Patients will often receive a combination of these treatments in more 
advanced melanomas (Garbe et al., 2010). Table 3 summarizes current treatment options in 
the United States (American Cancer Society, 2011; Kingham et al. 2010). 
Surgery usually is the first choice for the treatment of malignant melanoma if it is resectable. 
A safety margin around the border of the primary tumour is an important factors for 
consideration. The safety margin during excision is made in effort to avoid spread of the 
primary tumour to the surrounding skin. The size of the margins for optimal care is still 
debatable. Five trials were recently reviewed, and examined to determine whether a narrow 
margin, defined as 1 cm to 2 cm, had better outcome survival than a wide margin of 3 cm to 
5 cm. The reviewed trials only involved those with invasive melanoma, and not melanoma 
in situ. No significant difference was found in the overall survival between the narrow or 
wide excision margins, although there is an estimated small increase in survival in the wide  
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STAGE PRIMARY TUMOUR REGIONAL NODES METASTASES 
0; in 
situ 
Confined to the epidermis None None 
IA Confined to skin 
Tumour thickness of ≤1.0mm 
Without ulceration 
None None 
IB Confined to skin 
AND 
Tumour thickness of ≤1.0mm, with ulceration 
OR 
Tumour thickness of 1.01 – 2.0mm, without 
ulceration 
None None 
IIA Tumour thickness of 1.01 – 2.0mm, with ulceration 
Tumour thickness of 2.01 – 4.0mm, without 
ulceration 
None None 
IIB Tumour thickness of 2.01 – 4.0mm, with ulceration 
Tumour thickness of > 4.0mm, without ulceration 
None None 
IIC Tumour thickness of > 4.0mm, with ulceration None None 
IIIA Any tumour thickness, without ulceration Micrometastases None 
IIIB Any tumour thickness, with ulceration 
OR 
Any tumour thickness, without ulceration 
OR 
Any tumour thickness, with or without ulceration 
Micrometastases 
 
Up to 3 
macrometastases 
 
None, but satellite 
metastases and/or in-
transit metastases 
None 
IIIC Any tumour thickness, with ulceration 
OR 
Any tumour thickness, with or without ulceration 
Up to 3 
macrometastases 
 
4 or more 
macrometastases or 
capsule transgressing 
lymph node 
metastases, or satellite 
and/or in-transit 
metastases affecting 
the lymph nodes 
None 
IV Has spread to internal organs, beyond the nearest 
lymph node to other lymph nodes, or areas of skin 
far from original tumour 
Any nodal 
involvement 
Including 
distant 
metastases 
Table 2. The TMN classification of melanoma (Balch et al., 2009) 
excision group. Therefore, these trials provide insufficient evidence for defining the most 
favourable surgical excision margin in primary cutaneous melanoma (Sladden et al., 2010). 
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Unfortunately, metastatic forms of melanoma still have a high mortality rate due to its lack 
of response to systemic treatments. Numerous novel methods and approaches have been 
studied for the management of melanoma and although they were associated with increased 
toxicity and cost of treatment, some of the results showed potential for treatment of 
melanoma. Chemoimmunotherapy (or biochemotherapy), which is a combination of 
chemotherapy and immunotherapy, is one such approach that resulted in improvements 
although it still remains unclear whether it is clinically  beneficial as compared to the 
standard chemotherapy alone. A Cochrane review found that there is currently inconclusive 
evidence to support the use of chemoimmunotherapy in treating metastatic malignant 
melanoma as trials have not shown a difference in survival rates.  In addition, there is also 
an increase risk of toxic effects (Sasse et al., 2007). 
 
STAGE TREATMENT 
0; in situ - Surgical excision with safety margin of 0.5 cm 
- Use of imiquimod cream is controversial 
I - Surgical excision with safety margin of 1 cm if tumour thickness is less than 1 mm, 1 
– 2 cm if tumour thickness is 1 – 2 mm 
- Consider a SLNB 
II - Surgical excision with safety margin of 1 – 2 cm if tumour thickness is 1 – 2 mm, 2 cm 
if tumour thickness is greater than 2 mm 
- SLNB 
- If tumour is greater than 4 mm thick, or lymph nodes is cancerous, adjuvant therapy 
with interferon is considered 
III - Surgical excision of all melanoma (safety margin as in stage II) with lymph node 
dissection 
- Adjuvant therapy with interferon 
- If not all melanomas are excised, consider injections of bacilli Calmette-Guerin (BCG) 
vaccine or interleukin-2 (IL2) 
- If melanoma of the limbs, consider chemotherapy with a heated solution of 
melphalan 
- Radiation therapy for the area of excised lymph nodes may be offered after surgery, 
especially if nodes contained cancerous cells 
- Consider chemotherapy, immunotherapy with cytokines, and 
chemoimmunotherapy 
IV - Surgical excision of tumours and metastases 
- Surgical excision of internal organ metastases may be possible 
- If surgery is not possible, may be treated with chemotherapy, immunotherapy, or 
radiation 
Table 3. Melanoma treatments according to stage 
1.3 Prevention 
Melanoma is a serious disease. Although prognosis is excellent for melanoma in situ, it 
decreases with increasing stages. Thus, methods of prevention and early detection should be 
considered in efforts to decrease the risk of melanoma. Early detection in melanoma is a key 
since melanomas have a tendency to metastasize early relative to the tumour mass (Garbe et 
al., 2010). As incidences increases, early prevention and treatment is becoming more crucial. 
Ultraviolet radiation has been implicated as a major environmental factor in the 
pathogenesis of melanoma. Protection from skin damage by ultraviolet radiation may play 
an important role in the prevention of melanoma. 
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2. Recently published phase III clinical studies 
Numerous clinical trials have attempted to find novel ways of targeting malignant 
melanoma, and to extend overall survival of patients. Although many clinical trials 
investigating melanoma have been completed, there has been a lack of real conclusive 
evidence to change current treatment options. A search of the recent literature was 
performed for the recent trials conducted on melanoma. The search was limited to only 
phase III clinical trials, published in English in the last five years. Due to limited space for 
this chapter, some of results from recent clinical studies in the field are summarized in the 
following section.  
2.1 Monoclonal antibodies 
Recently, the United States Food and Drug Administration (FDA) has approved ipilimumab 
(Yervoy), a fully human monoclonal antibody, as adjuvant immunotherapy for the 
treatment of metastatic melanoma. It is the first new drug approved for melanoma in over 
13 years. Dacarbazine was approved in 1975, and interleukin-2 was approved in 1998 (U. S. 
Food and Drug Administration, 2011). Ipilimumab was approved by the FDA mainly based 
on an increase in overall survival in patients with late-stage melanoma in phase III clinical 
trials (Hodi et al., 2010). This is considered to be a significant improvement since there are 
limited options for patients with metastatic melanoma. Ipilimumab acts by inhibiting the 
cytotoxic T-lymphocyte associated-antigen 4 (CTLA-4). The antigen is thought to slow down 
or inactivate the body’s immune system, and thus limiting its effect on cancerous cells. 
Therefore, ipilimumab may enhance the antitumour T-lymphocyte response to attack the 
tumours of melanoma patients (Hodi et al., 2010). 
During the trial, ipilimumab was administered intravenously at 3 mg/kg of body weight, 
with or without a glycoprotein 100 (gp100) peptide vaccine, every 3 weeks for up to four 
treatments in the induction phase of the treatment. Additionally, a maintenance dose at 
every 12-week intervals was given in some studies (Hodi et al., 2010). It is interesting to note 
that the trial compared ipilimumab against an experimental vaccine, and not a placebo or 
standard treatment. The drug’s safety and effectiveness was determined from a single 
international study of 676 patients, all of whom had metastatic melanoma that may have not 
been surgically removed, and that were refractive to other treatment methods. Since 
ipilumumab is a monoclonal antibody and immunogenic, side effects commonly associated 
with the novel compound include fatigue, diarrhea, pruritis, endocrine deficiencies, and 
colitis. In 12.9% of patients studied, there was severe to fatal autoimmune reactions (Hodi et 
al., 2010). Thus adjuvant immunotherapy with ipilimumab is approved with a Risk 
Evaluation and Mitigation Strategy (U. S. Food and Drug Administration, 2011). Physicians 
must be vigilant in detecting patients with these serious side effects. 
Due to ipilimumab’s effect on the immune system, it may take some time to have an effect in 
a melanoma patient. Thus patients with rapidly progressive metastatic melanoma may not 
benefit from the treatment (Hodi et al., 2010). Currently, research efforts to identify 
biomarkers that predict the outcome due to ipilimumab is being conducted in hopes of 
determining a selectively way to conduct the adjuvant therapy. 
Ipilimumab was hypothesized to act through a human leukocyte antigen (HLA) 
independent mechanism, and thus most trials enrolled subjects into their study without 
regards to HLA subtype. It should be noted that the phase III trial restricted enrolment of 
subjects to class-I-HLA-A*0201-positive because of the use of HLA-A*0201-restricted gp100 
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vaccine in two of the three arms. Thus a retrospective analysis was conducted to determined 
whether ipilimumab could treat patients regardless of their HLA-A*0201status. The pooled 
efficacy and safety data were analyzed according to HLA-A*0201 status and found no 
difference in the overall survival using ipilimumab in advanced melanoma (Wolchok et al., 
2010). However, the interpretation of the results should be made with caution because of the 
nature of the analysis. 
2.2 Cytokines 
2.2.1 Interferon alpha-2b 
It is postulated that the benefits of interferon alpha-2b is dependent on the dose and 
duration of the treatment. A high-dose interferon alpha (IFN-α) regimen with an induction 
phase of maximally tolerated dosages (20 MU/m2 per day) by intravenous (IV) therapy for 
the initial 4 weeks has shown prolongation of overall survival (OS) and relapse-free survival 
(RFS) in comparison with observation in study E1684 (Kirkwood et al., 2009). Following this 
study, a prospective randomized study was conducted to compare intravenous induction 
therapy versus a full year of high-dose interferon, with primary endpoints of RFS and OS 
for patients with stage IIB, IIC, and III melanoma. Treatment was initiated within 56 days of 
curative surgery. Patients were randomly assigned to receive IFN-α-2b 15 MU/m2 IV for 
five times a week for 4 weeks (arm A) versus the same regimen followed by IFN-α-2b 10 
MU (flat dose) administered subcutaneously three times a week for 48 weeks (arm B). 
Between 1998 and 2004, 364 patients were enrolled (353 eligible: arm A, n = 177; arm B, n = 
176). At a median follow-up of 63 months (95% CI, 58.1 to 67.7), the median RFS was 24.1 
months versus 27.9 months (P = 0 .9) and the median OS was 64.4 months versus 65.3 
months (P = 0.49). Patients in arm B had more grade 1 to grade 2 hepatotoxicity, nausea, 
vomiting, alopecia, and neurologic toxicity. Thus the study concluded that there is no 
difference between a one month and a one year treatment in terms of relapsed-free or 
overall survival (Pectasides et al., 2009). 
High dose interferon alpha-2b is however associated with toxic effects. To investigate 
whether the use of an intermediate-dose of the interferon alpha-2b improves the overall 
benefit-risk ratio, a study was conducted in 855 patients in Nordic countries, who had either 
stage IIB, IIC, or III resected cutaneous melanoma. The data did not find intermediate 
adjuvant therapy to be significant in improving the overall survival of patients (Hansson et 
al., 2011). 
Low dose interferon alpha has been shown to provide patients with disease-free survival 
benefits in clinical trials in which patients had clinically lymph-node negative melanoma. 
Since there is a lack of knowledge on the proper duration of adjuvant treatment, a 
Dermatology Cooperative Oncology Group (DeCOG) trial investigated whether extending 
low dose interferon treatment from 18 months to 60 months would be beneficial. The trial 
found no significant clinical benefit in patients suffering from intermediate and high-risk 
primary melanoma (Hauschild et al., 2010). 
The DeCOG trial also evaluated the patients’ psychiatric symptoms before and during the 
adjuvant therapy.  A higher pretreatment depression score, as determined by the Beck 
Depression Inventory and the Symptom Check List 90-Revised, was determined to be a risk 
factor for early drop-out during treatment. Therefore, it is recommended that pretreatment 
screening be completed and an interdisciplinary care be considered when treating patients 
(Heinze et al., 2010). 
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2.2.2 Pegylated interferon alpha-2b 
The European Organisation for Research and Treatment of Cancer (EORTC) 18991 trial was 
conducted in order to compare adjuvant pegylated interferon alpha-2b therapy to 
observation alone in resected stage III melanoma (Eggermont et al., 2008). The purpose was 
to establish whether pegylated interferon alpha-2b could be tolerated over long exposures. 
The randomised phase III trial enrolled 1256 patients, and had stratified random assignment 
to either the treatment or observation group. The treatment group (n = 627) received 6 
mug/kg of pegylated interferon alpha-2b per week for 8 weeks in the induction phase, then 
3 mug/kg per week for 5 years in the maintenance phase of the trial. The primary endpoint 
was recurrence-free survival. The data were analyzed for intention-to-treat population. 
Results showed a statistically significant and sustained effect on recurrence-free survival 
with patients assigned to the adjuvant therapy. However, there was no difference found 
between the groups in overall survival. Additionally, patients receiving the pegylated 
interferon alpha-2b were at a higher risk of therapy related adverse events, such as 
hepatotoxicity and depression, and thus the treatment was discontinued (Eggermont et al., 
2008, 2010). 
In a clinical trial by the EORTC Melanoma Group, the health-related quality of life (HRQOL) 
effects of adjuvant therapy with pegylated interferon alpha-2b versus observation in 
resected stage III melanoma patients was assessed by the  EORTC Quality of Life 
Questionnaire C30 (Bottomley et al., 2009). It found that although pegylated interferon 
alpha-2b lead to a sustained and significant improvement in relapse-free survival, there was 
no significant difference in the overall survival. Additionally, there was a negative effect on 
global HRQOL and selected symptoms in melanoma patients undergoing the treatment. 
Patients on adjuvant therapy suffered from fatigue and loss of appetite statistically more so 
than the observation group. The effect was also clinically significant. Additionally, they also 
had statistically higher rates of dyspnea, as found at 3 months and 3 years after baseline.  
Patients also reported statistically greater frequency of fevers, headaches, and sore muscle or 
stiffness as compared with the observation group. A limitation in this trial was the drop-out 
rate in which few patients remained in the trial at 4 and 5 years after baseline. The high 
drop-out rate seriously undermines the long-term HRQOL analysis (Bottomley et al., 2009). 
The prognostic significance of autoantibodies in the EORTC 18991 trial was analyzed by 
comparing the long-term administration of pegylated interferon with observation. The 
study analyzed 220 patients (out of 296 that were initially tested) for anticardiolipin, 
antithyroglobulin, and antinuclear antibodies by an enzyme-linked immunosorbent assay at 
6 months intervals throughout the trial. Results found that there was no significance in the 
appearance of autoantibodies as a prognostic or predictive factor for outcomes in melanoma 
patients treated with pegylated interferon (Bouwhuis et al., 2010). 
2.2.3 Biochemotherapy with interferon alpha-2b 
A randomized trial was conducted to compare the clinical benefits of biochemotherapy to 
adjuvant interferon-alpha-2b in high risk recurrent melanoma patients (Kim et al., 2009). 
This study enrolled 138 patients, and divided them into three groups: biochemotherapy  
(n = 71), high-dose interferon (n = 34), and intermediate-dose interferon (n = 33). The 
biochemotherapy group received cisplatin at 20 mg/m2 IV on days 1–4, vinblastine at 1.5 
mg/m2 IV on days 1–4, dacarbazine at 800 mg/m2 IV on day 1, interferon-alpha-2b at 
5MU/m2 s.c. on days 1–5 and interleukin-2 at 9MU/m2 for a daily continuous IV infusion 
over days 1 - 4. The high-dose interferon-alpha-2b group received 20 MU/m2 IV for 5 days a 
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week for 4 weeks, followed by 10 MU/m2 s.c. injection three times a week for 48 weeks. The 
intermediate-dose interferon-alpha-2b group received 10 MU/m2 s.c. injection three times a 
week for 52 weeks. The study found that biochemotherapy is not more effective than 
adjuvant therapy with interferon. Also, there was no significant difference between the 
high-dose and intermediate-dose interferon in terms of RFS or OS. Thus, the findings 
precipitated the early termination of the trial (Kim et al., 2009). 
Another study on patients with metastatic malignant melanoma was conducted in order to 
compare cisplatin, vinblastine, and dacarbazine (CVD) either alone or concurrently with 
interleukin-2 and interferon alfa-2b (biochemotherapy). The treatments were given at every 
21-day intervals, for a maximum of 4 cycles, and the tumour response was measured after 
the second and fourth cycles, and every 3 months thereafter.  The study assessed 395 
patients, who were initially randomized and balanced for stratification factors and other 
prognostic factors. The patients receiving biochemotherapy had a slightly better response 
rate and longer median progression-free survival than with chemotherapy, but it did not 
translate to overall survival. Therefore, the study concluded that biochemotherapy should 
not be considered as a standard of care for metastatic melanoma due to its high toxicity and 
complexity in comparison to standard chemotherapy (Atkins et al., 2008). 
A multicenter trial was conducted to compare the effect of polychemotherapy through a 
CVD regimen against CVD with interleukin-2 and interferon-alpha-2b in patients with 
metastatic melanoma. A total of 151 patients were randomized in the study to two arms: 75 
participants on arm A which received cisplatin 30 mg/m2 on days 1-3, vindesine 2.5 mg/m2 
on day 1 and dacarbazine 250 mg/m2 on days 1-3, while 76 participants on arm B which 
received the same CVD scheme plus s.c. interleukin-2 on days 1-5 and 8-15 and interferon-
alpha-2b on days 1-5. Both arms ran on a 21-day cycle. The study was conducted in patients 
with untreated metastatic melanoma, and response was assessed every two cycles. 
Measures included the response rate, median time to progression, and median OS. 
Although biochemotherapy showed a better response rate, it is not better than 
chemotherapy alone since it did not improve median time to progression or OS. Therefore, 
this study also concluded that biochemotherapy should not be a standard of care for 
metastatic melanoma (Bajetta et al., 2006). 
In a German phase III trial, adjuvant low-dose interferon alpha-2a with or without 
dacarbazine, was compared to surgery alone in an observation group. A total of 444 patients 
who had received a complete lymph node dissection for pathologically proven regional 
node involvement were recruited in 42 centers (Garbe et al., 2008). Patients were either 
given 3 MU of interferon alpha-2a subcutaneously 3 times a week for 2 years or the same 
doses of interferon alpha-2a plus dacarbazine 850 mg/m2 every 4-8 weeks for 2 years or 
observation alone. A total of 441 patients results were used in intention-to-treat analysis, 
and disease-free survival (DFS) and OS were assessed. Results found that patients on the 
low-dose interferon had significantly better DFS and OS. Additionally, results showed that 
dacarbazine reversed the advantageous effect of the low-dose interferon alpha-2a therapy 
(Garbe et al., 2008). 
In a retrospective study of the EORTC 18951 biochemotherapy trial, results were used to 
determine whether pretreatment levels of neutrophils and leukocytes in a blood count could 
be independent predictors for short overall survival for stage IV melanoma patients 
undergoing interleukin-2 based immunotherapy. Patients in the trial were treated with 
dacarbazine, cisplatin, and interferon alpha, with or without interleukin-2. Results showed 
that elevated pretreatment neutrophils in the blood were an independent prognostic factor 
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for short OS, while elevated leukocytes counts were prognostic for short OS and 
progression-free survival. Therefore, both neutrophils and leukocytes counts may be used as 
stratification factors in future clinical trials (Schmidt et al., 2007). 
2.3 Vaccines 
Vitespen is an autologous tumour-derived heat shock protein gp96 peptide complex 
vaccine. An open-label phase III trial was conducted in which vitespen was compared with 
the physician’s choice for treatment for stage IV melanoma patients (Testori et al., 2008). 
Patients (n = 322) were randomly assigned in a 2:1 ratio to receive vitespen or physician's 
choice of a treatment containing one or more of the following: dacarbazine, temozolomide, 
interleukin-2, or complete tumor resection. Temozolomide was found to have comparable 
activity as dacarbazine in a systematic review. It also has the additional advantage of being 
an oral therapy that can cross the blood-brain barrier (Quirt et al., 2007). Patients were 
monitored for safety and overall survival. Patients in the vitespen vaccine group received a 
variable number of injections (ranging from 0 to 87, with a median of 6). Intention-to-treat 
analysis showed that OS in the vitespen group is not statistically different from that of the 
physician’s choice group. Exploratory landmark analyses show that patients in the M1a and 
M1b substages receiving a larger number of vitespen immunizations survived longer than 
those receiving fewer such treatments. Such difference was not detected for substage M1c 
patients (Testori et al., 2008).  
Another randomized phase III trial was conducted for demonstrating the superiority of 
autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine 
chemotherapy in stage IV melanoma patients. Dacarbazine was given at 850 mg/m2 
intravenously at a 4-week interval. DC vaccines loaded with MHC class I and II-restricted 
peptides were applied subcutaneously at a 2-week interval for the first five vaccinations and 
every 4 weeks thereafter. The primary endpoint was objective response, while secondary 
measures included toxicity, OS, and progression-free survival. At the time of the first 
interim analysis for the intention-to-treat population, 55 patients had been enrolled into the 
dacarbazine-arm and 53 into the DC-arm. The objective response was low (dacarbazine: 
5.5%, DC: 3.8%), but not significantly different in the two arms. The Data Safety & 
Monitoring Board recommended closure of the study. Thus, DC vaccination could not be 
demonstrated to be more effective than dacarbazine in stage IV melanoma patients 
(Schadendorf, et al, 2006).  
In the last decade, most published clinical trials on vaccines for melanoma were conducted 
at an early stage of development (e.g. phase I and phase II). Chi and Dudek (2011) 
conducted a systematic review and meta-analysis on the clinical trials pertaining to 
melanoma vaccine published between January 1, 1990 and May 1, 2010. The authors 
concluded that a melanoma-specific immune response predicted longer overall survival, 
although no evidence was found that vaccine therapy provides better overall disease control 
or overall survival compared with other treatments (Chi & Dudek, 2011). 
2.4 Small molecules  
Lenalidomide is a new compound under investigation for the treatment of metastatic 
malignant melanoma. Lenalidomide has shown effective antitumour activity against 
metastatic melanoma in an animal model (Payvandi et al., 2009). It was studied in a phase 
II/III trial that compared the efficacy and safety at two different doses (5 mg or 25 mg) for 
patients with relapsed metastatic melanoma refractory to previous treatments including 
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dacarbazine, interleukin-2, interferon alpha, and temozolomide. The results did not find a 
difference in the overall survival, response rate, or time to progression between the different 
dosing regimes. In addition, treatment with lenalidomide caused an observable 
myelosuppression (Glaspy et al., 2009). 
An international multicenter, randomized, double-blind phase II/III trial was also 
undertaken to assess the efficacy and safety of lenalidomide, given at 25 mg per day for 21 
days in a 28-day cycle, as compared to placebo in 306 patients with refractory stage IV 
metastatic malignant melanoma. The treatment was continued until there was progression 
of disease or an unacceptable toxicity. Results found that there was no significant difference 
between the use of lenalidomide and placebo in overall survival of the patient. Statistically, 
there was also no benefit in tumour response and time to progression (Eisen et al., 2010).  
Sorafenib is a multikinase inhibitor that prevents tumor cell proliferation and angiogenesis 
through receptor tyrosine kinases, vascular endothelial growth factor receptor (VEGFR)-1,  
-2, -3, and platelet derived growth factor receptor-ǂ and -ǃ, and the Raf/MEK/ERK 
pathway at the level of Raf kinase (Wilhelm, et al, 2004). A phase III trial was conducted in 
270 patients to evaluate the efficacy and safety of sorafenib with carboplastin and paclitaxel 
in comparison with placebo and paclitaxel in advanced melanoma patients who had 
previously received dacarbazine or temozolomide therapy. The primary efficacy endpoint 
was progression-free survival, with secondary and tertiary endpoints included overall 
survival and incidence of best response, respectively. As the results did not find any 
improvements with sorafenib plus paclitaxel over placebo plus paclitaxel, the regimen 
cannot be recommended for second-line treatment in advanced melanoma (Hauschild et al., 
2009).  
2.5 Adoptive therapy using tumor infiltrating lymphocytes 
Benlalam et al. (2007) reported a study on the adoptive therapy of cancer using tumour 
infiltrating lymphocytes (TIL) in stage III melanoma patients. The patients received 
autologous interleukin-2 or TIL with interleukin-2 after complete tumour resection. They 
discovered that infusion of Melan-A/MART-1 reactive TIL is correlated with a longer 
relapse-free survival for patients with HLA-A2. The authors indicate that Melan-A/MART-1 
antigen may serve as a target for melanoma immunotherapy (Benlalam et al., 2007). 
3. Recently completed or ongoing phase III clinical trials 
In the last five years, there were over 700 registered trials using ‘melanoma’ as a search term 
in the United States clinical trial registry. When the search was refined to phase III trials that 
started from 2006 – 2010, inclusive, it narrowed down the field to 40 studies. Out of the 40 
trials: 7 were completed, 24 were active or recruiting, 3 have an unknown status, 1 was no 
longer available, 2 were suspended, and 3 were terminated. The following briefly 
summarize some of the phase III clinical trials registered on clinicaltrials.gov in the last five 
years (U. S. National Institute of Health, 2011). All the following information was obtained 
from the registry unless otherwise noted. 
3.1 Interferon-alpha 
A Nordic adjuvant interferon trial was completed by giving patients an intermediate dose of 
interferon-alpha-2b after surgery for high risk melanoma. High risk melanoma patients were 
defined as T4N0M0 or TxN1-2M0. The study had three arms: control, adjuvant interferon  
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TRIAL THERAPIES COMPARED (REGIMEN) TARGET 
POPULATION 
SAMPLE 
SIZE 
STATUS 
NCT01259934 Interferon alpha2b 
(1 year: s.c. 10 MU for 5 days 
a week for 4 weeks, with a 
maintenance dose of 10 MU 
3 days a week for 1 year 
Or, 2 year: s.c. 10 MU for  
5 days a week for 4 weeks, 
with a maintenance dose of 
10 MU 3 days a week for  
1 year) 
Observation High risk 
melanoma 
855 Completed 
NCT00447356 High dose interferon alpha 
(dosing not available) 
Observation Resected stage II 
and III 
1420 Unknown 
Table 4. Studies on interferon-alpha for the treatment of melanoma 
for one year, and adjuvant interferon for two years. It aimed to study overall survival as a 
primary end point, as well as relapse-free survival, side effects and quality of life for 
secondary endpoints. The results of the study were summarized in section 2. 
Another study was designed to determine the use of high dose interferon-alpha in patients 
with stage II or stage III melanoma that have been completely removed by surgery. The 
status is currently unknown since the information has not been verified recently. 
3.2 Ipilimumab 
 
TRIAL THERAPIES COMPARED (REGIMEN) TARGET 
POPULATION 
SAMPLE 
SIZE 
STATUS 
NCT00324155 Ipilimumab and 
dacarbazine 
(10 mg/kg once 
every 3 weeks for 10 
weeks, then once 
every 12 weeks at 
week 24; 850 mg/m2 
once every 3 weeks 
for 22 weeks, 
respectively) 
Placebo and 
dacarbazine 
(0 mg once every 3 
weeks for 10 weeks, 
then once every 12 
weeks at week 24; 
850 mg/m2 once 
every 3 weeks for 22 
weeks, respectively) 
Unresectable 
stage III or IV 
500 Active, but 
not 
recruiting 
NCT00636168 Ipilimumab 
(IV 10 mg/kg four 
times every 21 days, 
then once every 12 
week starting at 
week 24 for 3 years) 
Placebo 
(IV 0 mg/kg four 
times every 21 days, 
then once every 12 
week starting at 
week 24 for 3 years) 
High risk stage 
III 
950 Recruiting 
Table 5. Studies on ipilimumab for the treatment of melanoma 
Ipilimumab is an anti-CTLA-4 monoclonal antibody that was recently approved by the U.S. 
FDA for use in melanoma. Currently, a phase III trial (NCT00324155) is designed to assess 
the efficacy of ipilimumab at 10 mg/kg with dacarbazine against a control group of placebo 
and dacarbazine in patients with unresectable stage III or IV melanoma. Another 
ipilimumab trial (NCT00636168) is attempting to investigate whether the therapy is effective 
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as compared to placebo for stage III melanoma patients as adjuvant immunotherapy. The 
primary outcome measure is recurrence free survival, and secondary outcomes include OS, 
distant metastases-free survival, quality of life, and adverse events of ipilimumab as 
compared to placebo. 
3.3 Small molecules - tyrosine kinase inhibitors 
3.3.1 Targeting melanoma with a BRAF V600E mutation 
 
TRIAL THERAPIES COMPARED 
(REGIMEN) 
TARGET 
POPULATION 
SAMPLE 
SIZE 
STATUS 
NCT01006980; 
BRIM3 
RO5185426 
(oral 960 mg, 
twice daily) 
Dacarbazine 
(IV 1000 mg/m2 
every 3 weeks) 
Stage IIIc or IV 
with BRAF V600E 
positive mutation 
680 Recruiting 
NCT01227889 GSK2118436 
(oral 150 mg, 
twice daily) 
Dacarbazine 
(IV 1000 mg/m2 
every 3 weeks) 
Stage III and IV 
with BRAF 
mutation-positive 
tumour 
200 Recruiting 
NCT01245062 GSK1120212 
(dosing not 
available) 
Chemotherapy 
(dacarbazine or 
paclitaxel; dosing 
not available) 
Stage IIIc and IV 
with BRAF 
mutation-positive 
tumour 
297 Recruiting 
Table 6. Studies on compounds targeting melanoma with BRAF mutations 
BRAF belongs to the RAF family of protein kinases. The BRAF V600 mutation is seen in as 
high as 60% of melanoma patients. Small molecules RO5185426, GSK2118436 and GSK1120212 
are developed to inhibit the RAS/RAF/MEK/ERK signalling system, and thus inhibit cellular 
growth of melanoma. These molecules are currently in clinical trials to assess their efficacy. 
RO5185426 is being studied for efficacy, safety, and tolerability as compared to dacarbazine 
in previously untreated patients with unresectable stage IIIC or stage IV melanoma with 
BRAF V600E mutation. This is a randomized, open-label study using overall survival and 
progression-free survival as a primary outcome. The participants will be followed for 
approximately three years. 
An randomized trial is comparing the efficacy, safety, and tolerability of the oral agent 
GSK2118436, a BRAF inhibitor, against standard chemotherapy. It is conducted in patients 
with BRAF mutant-positive tumours in stage IIIc or stage IV malignant cutaneous 
melanoma. Subjects will be followed for two years to determine the progression-free 
survival. Secondary endpoints include OS, rate of treatment, overall response rate, duration 
of response, and validation of the BRAF mutation assay. This is another study trying to 
determine whether an agent could stop or slow melanoma progression in BRAF V600 
mutant patients by altering the MAP kinase pathway.  
Study NCT00796445 is an open-label randomized trial comparing the single agent 
GSK1120212 (a MEK inhibitor) against standard chemotherapy, in patients with BRAF 
mutant-positive tumours in stage IIIc or stage IV malignant cutaneous melanoma. The study 
intends to measure progression free survival of patients.  
3.3.2 Targeting melanoma with a c-Kit mutation 
Nilotinib (AMNN107) is a selective BCR-ABL inhibitor. Currently, a phase III trial also 
known as the TEAM (Tasigna Efficacy in Advanced Melanoma) trial is recruiting  
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TRIAL THERAPIES COMPARED  
(REGIMEN) 
TARGET POPULATION SAMPLE 
SIZE 
STATUS 
NCT01028222; 
TEAM 
Nilotinib 
(dosing not 
available) 
Dacarbazine 
(dosing not 
available) 
Ureseactable Stage III, and 
IV with c-Kit mutation 
120 Recruiting 
NCT01280565 Masitinib 
(7.5 mg/kg 
perday) 
Dacarbazine 
(IV 1000 mg/m2 
once every three 
days) 
Unresectable stage IIIb or 
IIIc, or IV with mutation at 
juxta membrane domain of 
c-Kit 
200 Recruiting 
Table 7. Studies on compounds targeting melanoma with c-Kit mutations 
metastastic and/or inoperative melanoma patients that also have a c-Kit mutation for the 
study. This interventional study will be compared against dacarbazine, and is intended to 
have crossover assignment. The primary outcome measures will be progression free 
survival. 
Mastinib is another novel tyrosine kinase inhibitor that has been implicated in pre-clinical 
trial results for the treatment of advanced melanoma patients with a c-Kit juxtamembrane 
mutation. It is currently undergoing a prospective randomized trial for safety and efficacy in 
stage III and stage IV melanoma patients with a mutation in the juxtamembrane domain of 
c-Kit. 
3.4 Treatment for choroidal melanoma 
 
TRIAL THERAPIES COMPARED TARGET 
POPULATION 
SAMPLE 
SIZE 
STATUS 
NCT00680225 Ranibizumab with 
Transpupillary 
Thermotherapy (TTT) - 
Indocyanine Green (ICG) 
based photodynamic 
therapy (PDT) 
(0.5 mg ranibizumab once a 
month for 6 months, TTT-
ICG once or twice a month 
starting at month 2) 
Not 
applicable
Choroidal 
melanoma 
10 Active, but 
not 
recruiting 
NCT00811200; 
TORR 
Ranibizumab 
(intravitreal injections of 0.5 
mg, three times for a month)
or triamcinolone acetonide 
(intravitreal injection of 4.0 
mg) 
Placebo Choroidal 
melanoma 
220 Not yet 
recruiting 
Table 8. Studies on choroidal melanoma treatments 
A currently active study is undertaken to study the safety and tolerability of intravitreal 
injection of ranibizumab combined with Transpupillary Thermotherapy (TTT) - Indocyanine 
Green (ICG) based photodynamic therapy (PDT) for use as adjuvant treatment in choroidal 
melanoma. The primary outcome is reduction in tumour size. 
Another study plans to research the change in visual acuity after treatment with 
ranibizumab or triamcinolone acetonide in patients with radiation retinopathy after 
irradiation of choroidal melanoma. This is important as many patients lose visual acuity 
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after treatment of uveal melanoma using radiation therapy and TTT because of the radiation 
retinopathy. This study postulated a decrease in such complication with administration of 
ranibizumab or triamcinolone acetonide. 
3.5 Vaccines 
 
TRIAL THERAPIES COMPARED (REGIMEN) TARGET 
POPULATION
SAMPLE 
SIZE 
STATUS 
NCT00477906 M-Vax with BCG, 
cyclophosphamide, 
and IL2 
(M-Vax vaccine: 
intradermal 
injection of 4 to 20 
million cells, 
weekly for 7 weeks, 
with a booster at 
month 6; 
cyclophosphamide 
at 300 mg/m2; IL2 
at 3 MU/m2 for 5 
days with a 16-day 
rest period) 
Placebo vaccine 
with BCG, 
cyclophosphamide, 
and IL2 
(placebo vaccine: 
intradermal injection 
of 4 to 20 million cells, 
weekly for 7 weeks, 
with a booster at 
month 6; 
cyclophosphamide at 
300 mg/m2; IL2 at 3 
MU/m2 for 5 days 
with a 16-day rest) 
Stage IV 387 Suspended 
NCT00395070 Allovectin-7 
(intralesional 
injection at 2 mg, 
weekly for 6 
consecutive weeks 
in a 8-week cycle) 
Dacarbazine 
(IV 1000 mg/m2 for 
one hour every 28 
days) 
or temozolomide 
(oral 150 – 200 
mg/m2 daily for five 
consecutive days in 
28-day cycle) 
Recurrent stage 
III or IV 
375 Active, but 
not 
recruiting 
NCT00769704 OncoVex GM-CSF 
(4 ml of 108 pfu/ml 
per injection) 
GM-CSF 
(s.c. 125 µg/m2 for 14 
days in 28-day cycle) 
Unresectable 
Stage IIIb, IIIc, 
and IV 
430 Recruiting 
Table 9. Studies on vaccines for the treatment of melanoma 
The M-Vax vaccine is an autologous hapten (dinitrophenyl) modified melanoma vaccine 
derived from a patients’ own cancer cells. In previous studies, the vaccine was shown to be 
able to stimulate the immune system of the patient to react against the melanoma. This 
study was designed to see whether the vaccine, with administration of low dose interleukin-
2 to increase effectiveness, could shrink stage IV melanomas. The vaccine is being studied 
for best overall anti-tumour response and percent of patients’ survival at two years as the 
primary endpoint, and for safety as a secondary endpoint. Eligible participants must have at 
least one melanoma tumour that can be resected to be made into a vaccine, and have stage 
IV metastatic melanoma of the lung and/or soft tissues. 
OncoVex GM-CSF is an oncolytic vaccine that contains oncolytic herpes simplex type 1 virus 
encoding granulocyte macrophage colony-stimulating factor (GM-CSF) and has shown 
durable complete remission in melanoma patients in phase II clinical trial. The product has 
commenced phase III clinical trials for metastatic melanoma. The Onco Vex (GM-CSF) 
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Pivotal Trial in Melanoma (OPTIM) trial is a phase III study on the effects of the vaccine for 
the treatment of unresectable stage III or stage IV melanoma. (Kaufman & Bines, 2010). 
Allovectin-7® is a plasmid-based vaccine expressing two genes (HLA-B7 and ǃ2 
microglobulin) that together form an MHC class-1 complex. The product is claimed to train 
the immune system (both innate and adaptive) to destroy tumour cells. The minimum 
treatment time for patients is 16 weeks, and involves weekly injections. The progression free 
survival, as well as the safety and tolerability of the product will be compared to that of 
dacarbazine. 
3.6 Antisense oligonucleotides 
 
TRIAL THERAPIES COMPARED (REGIMEN) TARGET 
POPULATION 
SAMPLE 
SIZE 
STATUS 
NCT00518895; 
AGENDA 
Genasense and 
dacarbazine 
(IV: Genasense at 7  
mg/kg per day for 5 
days in a 21-day 
cycle, with 
dacarbazine at 1000 
mg/m2 for 1 hour 
after Genasense, for 
up to 8 cycles) 
Placebo and 
dacarbazine 
(IV: 0.9% sodium 
chloride at 7  mg/kg 
per day for 5 days in 
a 21-day cycle, with 
dacarbazine at 1000 
mg/m2 for 1 hour 
after placebo, for up 
to 8 cycles) 
Unresectable or 
stage IV 
and low LDH 
300 Unknown 
Table 10. Studies on antisense oligonucleotides for the treatment of melanoma 
Genasense is oblimersen sodium, which is a Bcl-2 antisense oligonucleotide that is currently 
being studied for use in advanced melanoma. Genasense with dacarbazine as compared to 
placebo and dacarbazine is being compared in patients that have never received 
chemotherapy treatment and have a low baseline LDH. The primary endpoints are 
progression-free survival and overall survival. The secondary endpoints are response rate, 
durable response rate, duration of response, and safety. The estimated enrollment was 300 
patients with unresectable or stage IV and low LDH. Its current status is unknown as the 
information has not been updated recently. 
3.7 Other small molecules 
The study on ABI-007, which is a new preparation of paclitaxel (a mitotic inhibitor), is being 
conducted to determine its activity, safety, and tolerability in comparison to dacarbazine. 
This study is limited to patients that have metastatic melanoma, and were not previously 
treated with chemotherapy. ABI-007 contains the same medication as Abrazane, a 
chemotherapeutic agent approved by the FDA for metastatic breast cancer. 
An uncontrolled prospective study is currently studying the effects of imiquimod in patients 
who received surgical excision for lentigo maligna or lentigo maligna melanoma. Imiquimod 
cream contains an imidazoquinoline (a class of compounds first synthesized in 1980) as the 
active ingredient. The imiquimod cream treatment starts 6 weeks post-surgery and will last 
up to 12 weeks. The cream is to be applied once daily for three times per week and after 2 
weeks of treatment, may be increased to five times per week if there is no or minor 
inflammation. If no or little inflammation is detected at 4 weeks, the treatment will become a 
daily application. Patients will be followed up to five years for any recurrence of disease. 
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TRIAL THERAPIES COMPARED 
(REGIMEN) 
TARGET 
POPULATION 
SAMPLE 
SIZE 
STATUS 
NCT00864253 ABI-007 
(IV at 150 mg/m2 at 
day 1, 8, and 15 of 4 
week cycle) 
Dacarbazine 
(IV at 1000 
mg/m2 every 21 
days) 
Stage IV 514 Recruiting 
NCT01088737 
(non-randomized)
Imiquimod 
(5% cream applied 
once daily, three 
times per week) 
 Lantigo maligna 
or lantigo 
maligna 
melanoma 
60 Recruiting 
NCT01264874; 
MelaViD 
Vitamin D3 
(100000 IU every 50 
days for 3 years) 
Placebo 
(matched 
placebo) 
Resected  
stage II 
878 Not yet 
recruiting 
NCT00522834; 
SYMMETRY 
Elesclomol and 
paclitaxel 
(IV at213 mg/m2; 80 
mg/m2 for once a 
week for 3 weeks in 
a 4-week cycle, 
respectively) 
Paclitaxel 
(IV at 80 mg/m2 
once a week for 
3 weeks in a 4-
week cycle) 
Stage IV 630 Terminated 
NCT01006252; 
SUMMIT-1 
Tasisulam 
(IV individualized 
dose at day 1 of 28-
day cycle) 
Paclitaxel 
(IV at 80 mg/m2 
at day 1, 8,15 of 
28-day cycle) 
Stage IV 323 Terminated 
NCT00779714; 
ChemoSensMM 
Paclitaxel and 
cisplatin 
(200 mg/m2; 50 
mg/ m2 on day 1 of 
a 21 day cycle, 
respectively) 
Or treosulfan and 
cytarabine 
(2500 mg/m2 on 
day 2; 100 mg/ m2 
on day 1to 3 of a 21 
day cycle, 
respectively) 
Dacarbazine 
(1000 mg/m2 on 
day 1 of a 21 day 
cycle) 
Stage IV 360 Recruiting 
Table 11. Studies on other small molecules for treatment of melanoma 
The European Institute of Oncology is currently investigating vitamin D3 (cholecalciferol) 
supplementation as compared to placebo in a double blind trial for its effects in the 
recurrence of resected stage II melanoma patients. This study will determine whether 
vitamin D can be used as a preventative and therapeutic cancer agent. 
Eclesclomol is a synthesized chemical entity that induced the oxidative stress response of 
cells. The double blind trial was designed to assess the efficacy of Elesclomol with paclitaxel 
in progression free survival in stage IV melanoma patients who have never received 
chemotherapy. The study was terminated. The reason for the termination is unknown. 
Trials on Tasisulam as compared to paclitaxel have also been terminated for fear of greater 
mortality risks with the experimental drug. The study was designed to study the effect of 
Tasisulam on overall survival in metastatic melanoma patients. 
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Dacarbazine is the standard chemotherapy offered to melanoma patients for stage IV 
melanoma as other therapies have yet been proven more effective in a randomized clinical 
trial. A currently recruiting trial is attempting to establish the efficacy of an individualized 
combination chemotherapy that is sensitivity-directed. The combination chemotherapy 
being studied in stage IV melanoma patients are either paclitaxel with cisplatin, or 
treosulfan with cytarabine. The study also aims at determining whether an individual 
chemosensitivity index can be used as a prognostic biomarker for chemotherapy. The 
primary outcome measure is overall survival. 
3.8 Surgery and radiotherapy 
Table 12 lists some clinical trials on surgery and radiotherapy for melanoma described 
below. 
A currently active study is trying to investigate the effect sentinel lymph node dissection 
following a wide surgical excision on patients with cutaneous invasive melanoma. The trial 
has three arms: surgical excision only, surgical excision with SLNB, and surgical excision 
with SLNB and complete lymph node biopsy. The last of which will be given offered to 
subjects that have a positive sentinel lymph node detected. The research will determine if 
surgical resection with intraoperative lymphatic mapping and SLNB prolongs overall 
survival of subjects as compared to receiving only surgical resection. Patients will be 
followed for 10 years to determine the OS, as well as the disease-free survival as a secondary 
outcome measure. 
A currently active study by the Trans-Tasman Radiation Oncology Group (TROG) is trying 
to determine the effect of adjuvant radiotherapy for patients that have resected melanoma 
involving the lymph nodes, and that are at a high risk of having a recurrence of the disease. 
The trial intends to determine whether radiotherapy will result in adequate locoregional 
control of the disease, with secondary outcomes including disease-free survival, overall 
survival, toxicity, and quality of life. The stage III melanoma patients will be divided into 
two arms: one who will receive immediate radiotherapy after surgical resection, and one 
who will be observed with a delay offer of radiotherapy. 
In another TROG study, patients that have received a surgical intervention for melanoma 
and show histological features of neurotropism will be assessed for efficacy of radiation 
therapy as compared to observation. Neurotropism have been shown in uncontrolled 
studies to result in a higher risk of local reoccurrence of the disease. The radiation received 
will encompass the surgical bed with a margin, and starts three month after the surgery. The 
patient population studied is limited to neurotropic melanoma of the head and neck. The 
primary outcome will measure time to local relapse for five years, with secondary outcomes 
including relapse free survival, overall survival, time to relapse, cancer specific survival, 
patterns of relapse, and toxicity. Patients in the observational group will be offered 
radiotherapy if there is recurrence of the disease. 
Stage IV melanoma is difficult to treat, despite all the research on the subject. A surgical 
intervention is effective in certain population with solitary metastases, but not in patients 
with multiple metastases. Currently, a trial is attempting to establish a standardized initial 
approach for stage IV melanoma patients in hopes of prolonging survival and augment their 
quality of life. Medical therapy is currently the favoured approach as to prevent numerous 
patients from undergoing unnecessary surgery for what may turn into a rapidly invasive 
melanoma with occult metastases at multiple sites. Patients in the trial will be divided into 
three arms: one that receives a surgical intervention alone, one that receives a surgical 
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intervention and the bacillus Calmette-Guerin (BCG) vaccine as adjuvant immunotherapy, 
and one that receives best medical therapy. Patients receiving the BCG will receive a dose 
based on their pre-study tuberculin-reactivity with those that have a greater or equal to 10 
mm reactivity receiving half the standard dose of BCG, and those with greater or equal to 20 
mm receiving a quarter of the standard BCG dose. The last group will be treated at the 
discretion of their medical oncologist and surgeons, and will not initially receive a surgical 
intervention. The treatment they receive can range from standard treatment to experimental  
 
TRIAL THERAPIES COMPARED TARGET 
POPULATION
SAMPLE 
SIZE 
STATUS 
NCT00275496 Wide excision, 
sentinel lymph node 
dissection, and 
potential complete 
lymph node 
dissection 
Wide excision of 
primary melanoma 
Melanoma 2001 Active,  
but not 
recruiting 
NCT00287196 Radiotherapy 
(48 Gy at five 
fractions per week 
for twenty fractions, 
for a maximum of 30 
days of treatment 
time) 
Observation, with 
delayed 
radiotherapy 
(48 Gy at five 
fractions per week 
for twenty fractions, 
for a maximum of 30 
days of treatment 
time) 
Melanoma 
involving 
lymph nodes 
236 Active,  
but not 
recruiting 
NCT00975520 Surgery and 
radiation therapy 
(48 Gy in twenty 
fractions over 4 
weeks) 
Observation after 
surgery 
Completely 
resected 
primary 
melanoma with 
neurotropism 
100 Recruiting 
NCT01013623 Surgery, or surgery 
with 2 adjuvant 
doses of bacillus 
Calmette-Guerin 
(BCG given four 
weeks after surgery: 
eight separate 
intradermal 
injections, dosing 
determined by pre-
study tuberculin-
reactivity, with two 
doses given two 
weeks apart) 
Best medical therapy Resectable 
stage IV 
399 Recruiting 
NCT00297895 Completion 
lymphadenectomy 
Observation with 
nodal ultrasound 
Molecular or 
histopathologic
al evidence of 
metastases in 
sentinel node 
1925 Recruiting 
Table 12. Studies on surgery and radiotherapy for the treatment of melanoma 
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therapy in clinical trial. The subjects will be followed for their lifespan to determine overall 
survival. The study will also measure time to progression of metastatic sites, melanoma-
specific survival, and time to development of new metastatic disease sites. 
In another study on sentinel lymph node biopsy, melanoma patients that are sentinel node 
positive will be studied for melanoma-specific survival after receiving a complete 
lymphadenectomy in comparison with monitoring by nodal ultrasound. Subjects enrolled 
need to demonstrate either molecular or histopathological evidence of metastases in the 
sentinel lymph node, and will be followed for ten years. The observation group that receives 
monitoring by ultrasound will receive delayed complete lymphadanectomy if there is 
recurrence of disease. The completion lymphadenectomy involved complete dissection of 
the lymph nodes of the positive lymph node basin. 
4. Conclusion 
Melanoma is the deadliest form of skin cancer. Melanoma in situ is the earliest stage and is 
99% curable with just surgical removal of the tumour. With increasing melanoma stages, the 
prognosis of melanoma becomes worse and the mortality rate increases. Although many 
trials have been conducted, there has been a lack of real conclusive evidence for any major 
change to current treatment options based on published results. Many current clinical trials 
at the late stage of development are now ongoing in order to find novel ways of targeting 
malignant melanoma, and to extend overall survival of patients. These trials will provide 
additional information on the treatment of melanoma and may potentially lead to the 
development of newer, more effective therapies. 
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